About Dr. Baaklini
Dr. Lila R. Baaklini is a board certified anesthesiologist, who completed her residency at Yale-New Haven Medical Center, where she served as chief resident in her final year. Upon completing her residency, she spent one year as an HSS Regional Anesthesiology and Acute Pain Medicine fellow.
Departments
Insurance
If your insurance is not listed, please call our office if you have questions regarding your insurance coverage. If you have out-of-network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.
Credentials
Appointments
Attending Anesthesiologist, Hospital for Special Surgery
Clinical Instructor in Anesthesiology, Weill Cornell Medical College
Certification
Diplomate American Board of Anesthesiology, 2016
Awards
Chief Resident, Yale-New Haven Medical Center 2014-2015
Education
Medical: Rutgers, New Jersey Medical School, Newark, NJ, 2011
Internship: Rutgers, New Jersey Medical School, Newark, NJ, 2012
Residency: Yale, New Haven Medical Center, New Haven, CT, 2015
Fellowship: Regional Anesthesia and Acute Pain Medicine, Hospital for Special Surgery, 2016
State Licensure
New York
Languages
English
Industry Relationships
Industry Relationships
HSS has a long history of supporting appropriate relationships with industry because they advance HSS's mission to provide the highest quality patient care, improve patient mobility, and enhance the quality of life for all, and to advance the science of orthopedic surgery, rheumatology, and their related disciplines through research and education.
As of May 11, 2024, Dr. Baaklini reported no relationships with the healthcare industry.
HSS and its physicians make this information available to patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest and Commitment Policy prohibits physicians from collecting royalties on products they develop that are used on patients at HSS.
